Hagihara M, Ariyoshi T, Kuroki Y, Eguchi S, Higashi S, Mori T
Sci Rep. 2021; 11(1):15007.
PMID: 34294848
PMC: 8298451.
DOI: 10.1038/s41598-021-94572-z.
Li W, Wang A
BMC Microbiol. 2021; 21(1):55.
PMID: 33602143
PMC: 7893910.
DOI: 10.1186/s12866-021-02114-4.
Petrosillo N, Granata G, Cataldo M
Front Med (Lausanne). 2018; 5:96.
PMID: 29713630
PMC: 5911476.
DOI: 10.3389/fmed.2018.00096.
Asempa T, Nicolau D
Clin Interv Aging. 2017; 12:1799-1809.
PMID: 29123385
PMC: 5661493.
DOI: 10.2147/CIA.S149089.
Navalkele B, Lerner S
Open Forum Infect Dis. 2016; 3(2):ofw094.
PMID: 27419166
PMC: 4943546.
DOI: 10.1093/ofid/ofw094.
Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection.
Hung Y, Lee J, Lin H, Liu H, Wu Y, Tsai P
Antibiotics (Basel). 2016; 4(2):216-29.
PMID: 27025622
PMC: 4790331.
DOI: 10.3390/antibiotics4020216.
Recurrent Clostridium difficile infection: From colonization to cure.
Shields K, Araujo-Castillo R, Theethira T, Alonso C, Kelly C
Anaerobe. 2015; 34:59-73.
PMID: 25930686
PMC: 4492812.
DOI: 10.1016/j.anaerobe.2015.04.012.
The potential for emerging therapeutic options for Clostridium difficile infection.
Mathur H, Rea M, Cotter P, Ross R, Hill C
Gut Microbes. 2015; 5(6):696-710.
PMID: 25564777
PMC: 4615897.
DOI: 10.4161/19490976.2014.983768.
Effects of tigecycline and vancomycin administration on established Clostridium difficile infection.
Theriot C, Schumacher C, Bassis C, Seekatz A, Young V
Antimicrob Agents Chemother. 2014; 59(3):1596-604.
PMID: 25547352
PMC: 4325817.
DOI: 10.1128/AAC.04296-14.
Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection.
Britt N, Steed M, Potter E, Clough L
Infect Dis Ther. 2014; 3(2):321-31.
PMID: 25466443
PMC: 4269622.
DOI: 10.1007/s40121-014-0050-x.
Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.
Aldape M, Heeney D, Bryant A, Stevens D
J Antimicrob Chemother. 2014; 70(1):153-9.
PMID: 25151204
PMC: 4267498.
DOI: 10.1093/jac/dku325.
Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.
Bassis C, Theriot C, Young V
Antimicrob Agents Chemother. 2014; 58(5):2767-74.
PMID: 24590475
PMC: 3993203.
DOI: 10.1128/AAC.02262-13.
Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
Garneau J, Valiquette L, Fortier L
BMC Infect Dis. 2014; 14:29.
PMID: 24422950
PMC: 3897887.
DOI: 10.1186/1471-2334-14-29.
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.
Tsutsumi L, Owusu Y, Hurdle J, Sun D
Curr Top Med Chem. 2013; 14(1):152-75.
PMID: 24236721
PMC: 3921470.
DOI: 10.2174/1568026613666131113154753.
Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection.
Bosse D, Lemire C, Ruel J, Cantin A, Menard F, Valiquette L
Infection. 2012; 41(2):579-82.
PMID: 22996384
DOI: 10.1007/s15010-012-0328-4.
Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin.
Lao 2nd D, Chiang T, Gomez E
Case Rep Med. 2012; 2012:702910.
PMID: 22829841
PMC: 3399506.
DOI: 10.1155/2012/702910.
Clostridium difficile Infection and Inflammatory Bowel Disease: A Review.
Sinh P, Barrett T, Yun L
Gastroenterol Res Pract. 2011; 2011:136064.
PMID: 21915178
PMC: 3171158.
DOI: 10.1155/2011/136064.
Recurrent Clostridium difficile infection: what are the treatment options?.
van Nispen tot Pannerden C, Verbon A, Kuipers E
Drugs. 2011; 71(7):853-68.
PMID: 21568363
DOI: 10.2165/11591230-000000000-00000.
Treatment of refractory and recurrent Clostridium difficile infection.
Surawicz C, Alexander J
Nat Rev Gastroenterol Hepatol. 2011; 8(6):330-9.
PMID: 21502971
DOI: 10.1038/nrgastro.2011.59.
Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.
Lin Y, Huang Y, Tsai P, Lee T, Lee N, Liao C
Antimicrob Agents Chemother. 2011; 55(4):1701-5.
PMID: 21263053
PMC: 3067156.
DOI: 10.1128/AAC.01440-10.
